Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.

Inhibitors of the molecular chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clinical development as potential treatments for cancer. In a preceding publication (DOI: 10.1021/jm100059d ) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range. This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead molecule 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclinical development and is currently being tested in man.

[1]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[2]  D. Wazer,et al.  ErbB2 Degradation Mediated by the Co-chaperone Protein CHIP* , 2003, The Journal of Biological Chemistry.

[3]  Giulio Rastelli,et al.  Structure‐Based and in silico Design of Hsp90 Inhibitors , 2009, ChemMedChem.

[4]  V. Cohn.  Drug metabolism. , 2020, Advances in biology of skin.

[5]  James R. Porter,et al.  Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. , 2006, Journal of medicinal chemistry.

[6]  B. Blagg,et al.  Hsp90 Inhibitors: Small Molecules that Transform the Hsp90 Protein Folding Machinery into a Catalyst for Protein Degradation. , 2006 .

[7]  F. Hartl,et al.  In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis , 1998, The Journal of cell biology.

[8]  Paul Workman,et al.  Drugging the Cancer Chaperone HSP90 , 2007, Annals of the New York Academy of Sciences.

[9]  X. Barril,et al.  Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. , 2009, Journal of Medicinal Chemistry.

[10]  A. Beresford,et al.  The metabolism and pharmacokinetics of amlodipine in humans and animals. , 1988, Journal of cardiovascular pharmacology.

[11]  Jonathan Weissman,et al.  Molecular Chaperones and Protein Quality Control , 2006, Cell.

[12]  L. Pearl,et al.  Structure and mechanism of the Hsp90 molecular chaperone machinery. , 2006, Annual review of biochemistry.

[13]  L. Pearl,et al.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.

[14]  K. Bhalla,et al.  Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia , 2010, Leukemia.

[15]  E Blanc,et al.  Electronic Reprint Biological Crystallography Modelling Prior Distributions of Atoms for Macromolecular Refinement and Completion Roversi Et Al. ¯ Prior Distributions for Macromolecular Refinement and Completion , 2022 .

[16]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[17]  David J. Diller,et al.  In Silico hERG Modeling: Challenges and Progress , 2009 .

[18]  Gurmeet Kaur,et al.  Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin , 2004, Clinical Cancer Research.

[19]  M. Bermejo,et al.  Pharmacokinetics in drug discovery. , 2008, Journal of pharmaceutical sciences.

[20]  W Bruce Turnbull,et al.  On the value of c: can low affinity systems be studied by isothermal titration calorimetry? , 2003, Journal of the American Chemical Society.

[21]  B. Sigurskjold,et al.  Exact analysis of competition ligand binding by displacement isothermal titration calorimetry. , 2000, Analytical biochemistry.

[22]  Neal Rosen,et al.  Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.

[23]  Martin K. Bayliss,et al.  Pharmacokinetics and Metabolism in Drug Design , 2002 .

[24]  Laura G. Dubois,et al.  Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. , 2009, Journal of medicinal chemistry.

[25]  S. Jackson,et al.  Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. , 2007, Journal of molecular biology.

[26]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[27]  J. Lyons,et al.  Biological characterization of AT 7519 , a small-molecule inhibitor of cyclin-dependent kinases , in human tumor cell lines , 2009 .

[28]  Maurizio Recanatini,et al.  hERG-related drug toxicity and models for predicting hERG liability and QT prolongation , 2009, Expert opinion on drug metabolism & toxicology.

[29]  L. Neckers,et al.  Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. , 2006, ACS chemical biology.

[30]  Mike Wood,et al.  4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.

[31]  William J Greenlee,et al.  Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. , 2005, Journal of medicinal chemistry.

[32]  Holly McDonough,et al.  CHIP: a link between the chaperone and proteasome systems , 2003, Cell stress & chaperones.

[33]  Y. Janin.  Heat Shock Protein 90 Inhibitors. A Text Book Example of Medicinal Chemistry , 2006 .

[34]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[35]  Gianni Chessari,et al.  Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. , 2010, Journal of medicinal chemistry.

[36]  A. Kuki,et al.  Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. , 2002, Journal of medicinal chemistry.

[37]  Sreenath V. Sharma,et al.  Development of radicicol analogues. , 2003, Current cancer drug targets.

[38]  L. Pearl,et al.  Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone , 1997, Cell.

[39]  Marcel L Verdonk,et al.  Automated Protein–Ligand Crystallography for Structure‐Based Drug Design , 2006, ChemMedChem.

[40]  K. Ballman,et al.  P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. , 2008, Cancer research.

[41]  Roman A. Laskowski,et al.  PDBsum: summaries and analyses of PDB structures , 2001, Nucleic Acids Res..

[42]  L. Neckers,et al.  The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.

[43]  P. Workman.  Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. , 2004, Cancer letters.

[44]  P. Workman,et al.  Death by chaperone: HSP90, HSP70 or both? , 2009, Cell cycle.

[45]  U. Banerji,et al.  Heat Shock Protein 90 as a Drug Target: Some Like It Hot , 2009, Clinical Cancer Research.

[46]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[47]  Michael J Hartshorn,et al.  AstexViewer: a visualisation aid for structure-based drug design. , 2002, Journal of computer-aided molecular design.

[48]  G. Robertson,et al.  HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.

[49]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[50]  A. Kamal,et al.  Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. , 2004, Journal of Medicinal Chemistry.

[51]  Xiong Cai,et al.  CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy , 2009, Clinical Cancer Research.

[52]  M. Drysdale,et al.  Medicinal chemistry of Hsp90 inhibitors. , 2008, Current topics in medicinal chemistry.

[53]  B. Teicher.  Tumor models for efficacy determination , 2006, Molecular Cancer Therapeutics.

[54]  L. Neckers,et al.  Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity , 2004, Investigational New Drugs.

[55]  L. Pearl,et al.  Expression and crystallization of the yeast Hsp82 chaperone, and preliminary x‐ray diffraction studies of the amino‐terminal domain , 1996, Proteins.

[56]  R. Scannevin,et al.  Heat shock protein 90: inhibitors in clinical trials. , 2010, Journal of medicinal chemistry.

[57]  M. Bibby,et al.  50 years of preclinical anticancer drug screening: empirical to target-driven approaches. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.